Literature DB >> 26102028

Phosphoproteomic analysis of kinase-deficient mice reveals multiple TAK1 targets in osteoclast differentiation.

Eriko Sumiya1, Takako Negishi-Koga2, Yusuke Nagai2, Ayako Suematsu2, Tomomi Suda2, Masahiro Shinohara3, Kojiro Sato3, Hideki Sanjo4, Shizuo Akira5, Hiroshi Takayanagi6.   

Abstract

TAK1 (encoded by Map3k7) is a mitogen-activated protein kinase kinase kinase (MAP3K), which activates the transcription factors AP-1 and NF-κB in response to receptor activator of NF-κB ligand (RANKL) stimulation, thus constituting a key regulator of osteoclast differentiation. Here we report the functional relevance of the kinase activity of TAK1 in the late stage of osteoclast differentiation in vivo using Ctsk-Cre mice and TAK1 mutant mice in which the TAK1 kinase domain was flanked by loxP. The Map3k7(flox/kd)Ctsk(Cre/+) mice displayed a severe osteopetrotic phenotype due to a marked decrease in osteoclast number. RANKL-induced activation of MAPK and NF-κB was impaired in the late stage of osteoclast differentiation. The absence of suppressive effect of an administered NF-κB inhibitor on the late stage of osteoclastogenesis led us to investigate unknown TAK1 targets in osteoclast differentiation. We performed a phosphoproteomic analysis of RANKL-stimulated osteoclast precursor cells from Map3k7(flox/kd)Ctsk(Cre/+) mice, revealing multiple targets regulated by TAK1 during osteoclastogenesis. Thus, TAK1 functions as a critical regulator of the phosophorylation status of various cellular proteins that govern osteoclastogenesis.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Osteoclast; Osteopetrosis; Phosphoproteome; RANKL; TAK1

Mesh:

Substances:

Year:  2015        PMID: 26102028     DOI: 10.1016/j.bbrc.2015.06.105

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  5 in total

1.  Innate immunity kinase TAK1 phosphorylates Rab1 on a hotspot for posttranslational modifications by host and pathogen.

Authors:  Rebecca S Levin; Nicholas T Hertz; Alma L Burlingame; Kevan M Shokat; Shaeri Mukherjee
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-01       Impact factor: 11.205

Review 2.  The Role of TAK1 in RANKL-Induced Osteoclastogenesis.

Authors:  Wu Jianwei; Tian Ye; Wang Hongwei; Li Dachuan; Zou Fei; Jiang Jianyuan; Wang Hongli
Journal:  Calcif Tissue Int       Date:  2022-03-14       Impact factor: 4.000

Review 3.  Recent advances in osteoclast biology.

Authors:  Takehito Ono; Tomoki Nakashima
Journal:  Histochem Cell Biol       Date:  2018-02-01       Impact factor: 4.304

4.  Stevioside Prevents Wear Particle-Induced Osteolysis by Inhibiting Osteoclastogenesis and Inflammatory Response via the Suppression of TAK1 Activation.

Authors:  Jiahong Meng; Chenhe Zhou; Bin Hu; Mengmeng Luo; Yute Yang; Yangxin Wang; Wei Wang; Guangyao Jiang; Jianqiao Hong; Sihao Li; Haobo Wu; Shigui Yan; Weiqi Yan
Journal:  Front Pharmacol       Date:  2018-09-26       Impact factor: 5.810

5.  Magnoflorine Suppresses MAPK and NF-κB Signaling to Prevent Inflammatory Osteolysis Induced by Titanium Particles In Vivo and Osteoclastogenesis via RANKL In Vitro.

Authors:  Zhenyu Sun; Junkai Zeng; Wenjuan Wang; Xinlin Jia; Qiang Wu; Degang Yu; Yuanqing Mao
Journal:  Front Pharmacol       Date:  2020-04-02       Impact factor: 5.810

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.